BR112021024787A2 - Métodos para ativar uma via de sinalização wnt, para intensificar a regeneração de tecido e para facilitar a interação de um receptor fzd2 ou fzd7 e um correceptor wnt, molécula de ligação multivalente, e, composição farmacêutica - Google Patents

Métodos para ativar uma via de sinalização wnt, para intensificar a regeneração de tecido e para facilitar a interação de um receptor fzd2 ou fzd7 e um correceptor wnt, molécula de ligação multivalente, e, composição farmacêutica

Info

Publication number
BR112021024787A2
BR112021024787A2 BR112021024787A BR112021024787A BR112021024787A2 BR 112021024787 A2 BR112021024787 A2 BR 112021024787A2 BR 112021024787 A BR112021024787 A BR 112021024787A BR 112021024787 A BR112021024787 A BR 112021024787A BR 112021024787 A2 BR112021024787 A2 BR 112021024787A2
Authority
BR
Brazil
Prior art keywords
receptor
wnt
methods
signaling pathway
binding molecule
Prior art date
Application number
BR112021024787A
Other languages
English (en)
Inventor
Sachdev Sidhu
Stephane Angers
Yuyong Tao
Original Assignee
Antlera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antlera Therapeutics Inc filed Critical Antlera Therapeutics Inc
Publication of BR112021024787A2 publication Critical patent/BR112021024787A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

métodos para ativar uma via de sinalização wnt, para intensificar a regeneração de tecido e para facilitar a interação de um receptor fzd2 ou fzd7 e um correceptor wnt, molécula de ligação multivalente, e, composição farmacêutica. são descritos neste documento métodos para afetar a ligação de uma molécula de ligação multivalente a um receptor fzd e um correceptor wnt em uma célula, em que a ligação da molécula de ligação multivalente ao receptor fzd e ao correceptor na célula ativa uma via de sinalização wnt. também são descritas aqui moléculas de ligação multivalentes compreendendo um domínio de ligação ao receptor fzd e um domínio de ligação do correceptor wnt em qualquer uma das extremidades de um domínio fc que ativam uma via de sinalização wnt e métodos para seu uso.
BR112021024787A 2019-06-11 2020-06-10 Métodos para ativar uma via de sinalização wnt, para intensificar a regeneração de tecido e para facilitar a interação de um receptor fzd2 ou fzd7 e um correceptor wnt, molécula de ligação multivalente, e, composição farmacêutica BR112021024787A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962860161P 2019-06-11 2019-06-11
PCT/IB2020/055463 WO2020250156A1 (en) 2019-06-11 2020-06-10 Multivalent fzd and wnt binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
BR112021024787A2 true BR112021024787A2 (pt) 2022-05-03

Family

ID=73782094

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024787A BR112021024787A2 (pt) 2019-06-11 2020-06-10 Métodos para ativar uma via de sinalização wnt, para intensificar a regeneração de tecido e para facilitar a interação de um receptor fzd2 ou fzd7 e um correceptor wnt, molécula de ligação multivalente, e, composição farmacêutica

Country Status (11)

Country Link
US (1) US20220315659A1 (pt)
EP (1) EP3983443A4 (pt)
JP (1) JP7377288B2 (pt)
KR (1) KR20220024460A (pt)
CN (1) CN114423784A (pt)
AU (1) AU2020291208A1 (pt)
BR (1) BR112021024787A2 (pt)
CA (1) CA3140580A1 (pt)
IL (1) IL288730A (pt)
MX (1) MX2021015439A (pt)
WO (1) WO2020250156A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018132572A1 (en) 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (rspo) surrogate molecules
WO2018140821A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
WO2022130342A1 (en) * 2020-12-18 2022-06-23 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2424567B1 (en) * 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
BR112014002716A2 (pt) * 2011-08-05 2017-06-13 Genentech Inc anticorpos anti-poliubiquitina e métodos de uso
WO2015023851A1 (en) * 2013-08-14 2015-02-19 The Governing Council Of The University Of Toronto Antibodies against frizzled proteins and methods of use thereof
US11142577B2 (en) * 2014-09-12 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University WNT signaling agonist molecules
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
US11773171B2 (en) * 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CA3129736A1 (en) * 2018-02-14 2019-08-22 Antlera Therapeutics Inc. Multivalent binding molecules activating wnt signaling and uses thereof

Also Published As

Publication number Publication date
KR20220024460A (ko) 2022-03-03
EP3983443A1 (en) 2022-04-20
JP2022536142A (ja) 2022-08-12
CA3140580A1 (en) 2020-12-17
US20220315659A1 (en) 2022-10-06
IL288730A (en) 2022-02-01
AU2020291208A1 (en) 2022-01-06
CN114423784A (zh) 2022-04-29
WO2020250156A1 (en) 2020-12-17
EP3983443A4 (en) 2023-06-07
JP7377288B2 (ja) 2023-11-09
MX2021015439A (es) 2022-03-11

Similar Documents

Publication Publication Date Title
BR112021024787A2 (pt) Métodos para ativar uma via de sinalização wnt, para intensificar a regeneração de tecido e para facilitar a interação de um receptor fzd2 ou fzd7 e um correceptor wnt, molécula de ligação multivalente, e, composição farmacêutica
PE20211696A1 (es) Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor
BR112019005895A2 (pt) moléculas de ligação que modulam uma atividade biológica expressa por uma célula
BR112019007267A2 (pt) anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes
BR112018002570A2 (pt) molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
UY38251A (es) Moléculas de unión contra bcma y usos de las mismas
CL2019000261A1 (es) Polipéptidos modificados y usos de los mismos.
BR112017027965A2 (pt) anticorpo receptor, proteína de fusão, fragmento de dna, vetor de expressão, célula, complexo de anticorpo receptor, usos de um anticorpo receptor e de uma proteína de fusão, e, métodos para tratamento de um distúrbio e de uma doença.
BR112016024515A2 (pt) proteínas do agonista do receptor trail de cadeia única
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
BR112018008068A2 (pt) moléculas de ligação que inibem o crescimento do câncer
CO2020010277A2 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
AR073072A1 (es) Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
CL2019001324A1 (es) Anticuerpos anti-met, moleculas de unión a antígeno bispecificas que se unen a met y métodos de uso de los mismos.
BR112014029585A2 (pt) neurotoxina botulínica engendrada
AR095596A1 (es) Moléculas de unión de cadena única comprendiendo n-terminal abp
BR112015004522A2 (pt) receptor de antígeno quimérico multicadeia e usos destes
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
BRPI1008692B8 (pt) anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
BR112018071686A2 (pt) exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
BR112012012887A2 (pt) minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito.
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
BR112018000632A8 (pt) Moléculas de anticorpo que ligam a cd79
BR112020009759A8 (pt) Anticorpos específicos para transcrito 3 semelhante à imunoglobulina (ilt3) e usos dos mesmos